Notes

Aerobic complications of COVID-19.
Background Aflatoxins are fungal secondary metabolites negatively affecting ruminant performance; however, little information is available on their impact on rumen fermentation. Aims This study aimed at determining the effects of different concentrations of aflatoxin B1 (AFB1) from Aspergillus flavus on in vitro gas production and ruminal fermentation parameters using two experiments (Exp.). Methods In Exp. 1, two concentration ranges (0, 0.5, 1, and 1.5 µg/ml of rumen inoculum as low and 0, 5, and 10 µg/ml as high concentration ranges) were used to evaluate AFB1 effect on gas production kinetics using 96-h incubations. In Exp. 2, only the high concentration range was used to investigate AFB1 effects on ruminal fermentation parameters using 24-h incubations. Results In the low concentration range, the half-time of asymptotic gas production (T1/2) increased and the fractional rate of gas production (µ) decreased linearly with AFB1 dosage (P less then 0.05). However, in the high concentration range, the asymptotic gas production (A) and T1/2 decreased; and the lag time (L) and "µ" increased linearly (P less then 0.001) by increasing the concentrations of AFB1. In Exp. 2, dry matter (DM) and organic matter (OM) disappearance, microbial biomass (MB) and total volatile fatty acids (TVFA) concentrations were depressed, but pH and ammonia-N concentration increased (P less then 0.01) by increasing the concentrations of AFB1. The pattern of rumen volatile fatty acids (VFAs) was also modified by AFB1, as the propionate proportion increased at the expense of acetate. Conclusion Aflatoxin B1 had an adverse effect on in vitro ruminal fermentation parameters in high concentration ranges (5 and 10 µg/ml).Background Diarrheagenic Escherichia coli (DEC) is regarded as a great public health concern all around the world causing diarrhoea which can be transmitted through food chain. Aims This study aimed to determine the contamination level and exact distribution rate of DEC in food products consumed by human. Methods Seven hundred and twenty samples of food from animal origin and fishes were analysed by conventional and molecular method for the presence of E. coli and two multiplex polymerase chain reaction (mPCR) for detection of DEC. Results Two hundred and eighty-three E. coli isolates were detected. selleck inhibitor The classification of DEC by two multiplex PCR assay yielded 84 DEC pathotypes. Enterotoxigenic E. coli (ETEC) was detected at high rates (75%) followed by shiga-toxigenic E. coli (STEC) and enterohemorrhagic E. coli (EHEC) (each of 9.5%), enteroaggregative E. coli (EAEC) (3.5%) and atypical enteropathogenic E. coli (aEPEC) (about 2.3%). The highest number of DEC (n=26; 21.6%) was observed from beef carcasses in abattoir while the lowest number (n=7; 5.8%) was noticed from burger samples (P0.05). Conclusion High DEC contamination rate that was observed is attributed to the poor hygienic practices during food processing. Therefore, a superior hygienic application is required.Listeria monocytogenes, as a foodborne pathogenic bacterium, is considered as major causative agent responsible for serious diseases in both humans and animals. Milk and dairy products are among the main sources of energy supply in the human, therefore contamination of these products with Listeria spp., especially L. monocytogenes, could lead to life threatening infections in a large population of people. Rapid and accurate detection of L. monocytogenes in milk and dairy products, vegetables, meat, poultry, and seafood products is needed to prevent its dissemination through the food chain. Upon contamination of food materials with this pathogen, increase in its antibiotic resistance rate can occur after exposure to preservatives, antibiotics, and stress conditions, which has now become another major public health concern emphasizing the need for special attention on its control along the food chain and management of the disease in the patients. This review provides an overview of researches with respect to the prevalence of Listeria spp., especially L. monocytogenes, in milk and dairy products, methods of their detection and typing, and current status of resistance rates to the antibiotics used for treatment of listeriosis.[This corrects the article DOI 10.1186/s13223-019-0391-9.]. © The Author(s) 2020.Background To evaluate the effects of fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, placebo-controlled, multicenter, stratified, parallel-group, non-inferiority study of fluticasone furoate 50 µg inhalation powder administered once daily. The study enrolled children (aged 5-11 years inclusive) with a documented diagnosis of asthma for ≥ 6 months and a Childhood Asthma Control Test score of > 19. After a 7-14-day run-in period, eligible subjects were stratified by age and randomized to fluticasone furoate 50 µg once daily or placebo once daily via ELLIPTA for 6 weeks. The primary endpoint was the change from baseline (expressed as a ratio) in 0-24-h weighted mean serum cortisol at the end of the treatment period. Results Fifty-six randomized subjects received fluticasone furoate 50 µg once daily and 55 received placebo. The primary analysis was performed in the serum cortisol population (n = 104) and demonstrated that fluticasone furoate 50 µg once daily was non-inferior to placebo (ratio = 0.93; 95% confidence interval 0.8096, 1.0620), as the lower limit of the 95% confidence interval for the geometric mean treatment ratio of fluticasone furoate 50 µg once daily versus placebo was greater than 0.80. Findings from the intent-to-treat population (n = 111) were similar. Conclusions Six weeks of treatment with inhaled fluticasone furoate 50 µg once daily had no clinically relevant effect on the hypothalamic-pituitary-adrenocortical axis function of children, as measured by 24-h serum cortisol profiles. The primary analysis showed that fluticasone furoate 50 µg once daily was non-inferior to placebo. Fluticasone furoate 50 µg once daily was well tolerated and no new safety concerns emerged during the study. Trial registration This study is registered in ClinicalTrials.gov (NCT02483975). Date of submission 25 June 2015. © The Author(s) 2020.
My Website: https://www.selleckchem.com/products/opb-171775.html